blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2830663

EP2830663 - FULLY HUMAN ANTIBODIES THAT BIND TO VEGFR2 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.12.2019
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  04.01.2019
FormerGrant of patent is intended
Status updated on  20.08.2018
FormerExamination is in progress
Status updated on  01.12.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, CA 92121 / US
[2019/46]
Former [2015/06]For all designated states
Sorrento Therapeutics, Inc.
6042 Comerstone Ct. West
Suite B
San Diego, CA 92121 / US
Inventor(s)01 / GASTWIRT, Randy
4083 Sequoia Street
San Diego, CA 92109 / US
02 / ZHOU, Heyue
15732 Potomac Ridge Road
San Diego, CA 92127 / US
03 / GRAY, John, Dixon
9878 Erma Road
Apt 38
San Diego, CA 92130 / US
04 / LU, Guodi
10771 Carmel Glen Trail
Unit 50
San Diego, CA 92130 / US
 [2016/25]
Former [2015/12]01 / GASTWIRT, Randy
4083 Sequoia Street
San Diego, CA 92109 / US
02 / ZHOU, Heyue
10936 Via Banco
San Diego, CA 92126 / US
03 / GRAY, John, Dixon
9878 Erma Road
Apt 38
San Diego, CA 92130 / US
04 / LU, Guodi
10771 Carmel Glen Trail
Unit 50
San Diego, CA 92130 / US
Former [2015/06]01 / GASTWIRT, Randy
4083 Sequoia Street
San Diego, CA 92109 / US
02 / ZHOU, Heyue
10936 Via Banco
San Diego, CA 92126 / US
03 / GRAY, John, Dixon
9878 Erma Road
Apt 38
San Diego, CA 92130 / US
04 / LU, Guodi
10771 Carmel Glen Trail
San Diego, CA 92130 / US
Representative(s)Lloyd, John Scott
Script IP Limited
Turnpike House
18 Bridge Street
Frome Somerset BA11 1BB / GB
[N/P]
Former [2015/06]Sterling IP
Orion House
Bessemer Road
Welwyn Garden City AL7 1HH / GB
Application number, filing date13770063.930.03.2013
[2019/06]
WO2013US34732
Priority number, dateUS201261618658P30.03.2012         Original published format: US 201261618658 P
[2015/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013149219
Date:03.10.2013
Language:EN
[2013/40]
Type: A2 Application without search report 
No.:EP2830663
Date:04.02.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.10.2013 takes the place of the publication of the European patent application.
[2015/06]
Type: B1 Patent specification 
No.:EP2830663
Date:06.02.2019
Language:EN
[2019/06]
Search report(s)International search report - published on:US21.11.2013
(Supplementary) European search report - dispatched on:EP24.06.2016
ClassificationIPC:A61K39/395, C07K16/22, C07K16/28
[2016/12]
CPC:
C07K16/2863 (EP); C07K16/22 (EP); A61K2039/505 (EP);
A61K2039/507 (EP); C07K2317/14 (EP); C07K2317/21 (EP);
C07K2317/24 (EP); C07K2317/73 (EP); C07K2317/92 (EP) (-)
Former IPC [2015/06]A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VOLLSTÄNDIG HUMANE, AN VEGFR2 BINDENDE ANTIKÖRPER[2015/06]
English:FULLY HUMAN ANTIBODIES THAT BIND TO VEGFR2[2015/06]
French:ANTICORPS COMPLÈTEMENT HUMAINS QUI SE LIENT À VEGFR2[2015/06]
Entry into regional phase17.09.2014National basic fee paid 
09.12.2014Search fee paid 
17.09.2014Designation fee(s) paid 
17.09.2014Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2015/06]
17.09.2014Examination requested  [2015/06]
09.12.2014Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2015/06]
09.12.2014Request for decision received: Application is deemed to be withdrawn
17.12.2014Result of request for decision (Application is deemed to be withdrawn): Request accepted
18.01.2017Amendment by applicant (claims and/or description)
04.12.2017Despatch of a communication from the examining division (Time limit: M06)
05.04.2018Reply to a communication from the examining division
21.08.2018Communication of intention to grant the patent
17.12.2018Fee for grant paid
17.12.2018Fee for publishing/printing paid
17.12.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.12.2017
Opposition(s)07.11.2019No opposition filed within time limit [2020/03]
Fees paidRenewal fee
27.03.2015Renewal fee patent year 03
31.03.2016Renewal fee patent year 04
27.03.2017Renewal fee patent year 05
27.03.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.03.2013
AL06.02.2019
AT06.02.2019
CY06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
MK06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
TR06.02.2019
IE30.03.2019
LU30.03.2019
MT30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
[2022/31]
Former [2021/32]HU30.03.2013
AL06.02.2019
AT06.02.2019
CY06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
TR06.02.2019
IE30.03.2019
LU30.03.2019
MT30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2021/26]AL06.02.2019
AT06.02.2019
CY06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
TR06.02.2019
IE30.03.2019
LU30.03.2019
MT30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/29]AL06.02.2019
AT06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
TR06.02.2019
IE30.03.2019
LU30.03.2019
MT30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/17]AL06.02.2019
AT06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
TR06.02.2019
IE30.03.2019
LU30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/12]AL06.02.2019
AT06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SI06.02.2019
SK06.02.2019
SM06.02.2019
IE30.03.2019
LU30.03.2019
BE31.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/09]AL06.02.2019
AT06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SK06.02.2019
SM06.02.2019
IE30.03.2019
LU30.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/03]AL06.02.2019
AT06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SK06.02.2019
SM06.02.2019
LU30.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2020/01]AL06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
MC06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SK06.02.2019
SM06.02.2019
LU30.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/52]AL06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
PL06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SK06.02.2019
SM06.02.2019
LU30.03.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/49]AL06.02.2019
CZ06.02.2019
DK06.02.2019
EE06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
RO06.02.2019
RS06.02.2019
SE06.02.2019
SK06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/48]DK06.02.2019
ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
RS06.02.2019
SE06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/47]ES06.02.2019
FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
RS06.02.2019
SE06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/46]FI06.02.2019
HR06.02.2019
IT06.02.2019
LT06.02.2019
LV06.02.2019
RS06.02.2019
SE06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/39]FI06.02.2019
HR06.02.2019
LT06.02.2019
LV06.02.2019
RS06.02.2019
SE06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
IS06.06.2019
PT06.06.2019
Former [2019/38]FI06.02.2019
LT06.02.2019
SE06.02.2019
BG06.05.2019
NO06.05.2019
GR07.05.2019
PT06.06.2019
Former [2019/37]FI06.02.2019
LT06.02.2019
SE06.02.2019
NO06.05.2019
GR07.05.2019
PT06.06.2019
Former [2019/34]FI06.02.2019
LT06.02.2019
SE06.02.2019
NO06.05.2019
PT06.06.2019
Former [2019/33]FI06.02.2019
LT06.02.2019
NO06.05.2019
PT06.06.2019
Documents cited:Search[A]WO0230984  (UAB RESEARCH FOUNDATION [US]) [A] 1-12* abstract *;
 [A]WO2009060198  (PEREGRINE PHARMACEUTICALS INC [US], et al) [A] 1-12 * abstract * * page 39, line 9 - page 66, line 31 *;
 [I]  - ZHANG HAIFAN ET AL, "Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2", LEUKEMIA AND LYMPHOMA, INFORMA HEALTHCARE, US, (20040901), vol. 45, no. 9, doi:10.1080/10428190410001712225, ISSN 1042-8194, pages 1887 - 1897, XP008096902 [I] 1-12 * abstract * * page 1887 - page 1889; figure 1 *

DOI:   http://dx.doi.org/10.1080/10428190410001712225
 [A]  - MIAO H Q ET AL, "Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 345, no. 1, doi:10.1016/J.BBRC.2006.04.119, ISSN 0006-291X, (20060623), pages 438 - 445, (20060623), XP024925104 [A] 1-12 * abstract * * page 439 - page 440; figure 1a *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2006.04.119
 [A]  - ZHU Z ET AL, "Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity", LEUKEMIA, MACMILLAN PRESS LTD, US, (20030301), vol. 17, no. 3, doi:10.1038/SJ.LEU.2402831, ISSN 0887-6924, pages 604 - 611, XP002508501 [A] 1-12 * abstract * * page 604 - page 610; table 1 *

DOI:   http://dx.doi.org/10.1038/sj.leu.2402831
 [A]  - JIMENEZ XENIA ET AL, "A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.", MOLECULAR CANCER THERAPEUTICS MAR 2005, (200503), vol. 4, no. 3, ISSN 1535-7163, pages 427 - 434, XP008178943 [A] 1-12 * abstract * * page 427 - page 429; figure 1 *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-04-0261
International search[A]WO2006017538  (DYAX CORP [US], et al);
 [A]US2009306348  (GOLDSTEIN JOEL [US], et al);
 [A]US2011038874  (TONG JIE [US], et al);
 [A]  - WICKI ET AL., "Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth", CLIN. CANCER RES., (20120115), vol. 18, no. 2, XP055162153

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-11-1102
by applicantUS3817827
 US3850752
 US3901654
 US4002531
 US4098876
 US4179337
 US4301144
 US4496689
 US4640835
 US4670417
 US4791192
 US4816567
 US4946778
 US5092885
 EP0473084
 US5112946
 US5192744
 US5202352
 WO9401451
 US5281698
 WO9410308
 US5382657
 US5582996
 US5807706
 US5824784
 US5877293
 US5886152
 US5932462
 US5959083
 US6010902
 WO0009560
 US6054297
 US2002044921
 US6395718
 US6462075
 US6465431
 US6475784
 US6482802
 US6482810
 US6500431
 US6500924
 US6518298
 US6521439
 US6524583
 US6525019
 US6538103
 US6544758
 US6544947
 US6548477
 US6559126
 US6569845
 US6573256
 US6696245
 US6846634
    - FOLKMAN; KLAGSBRUN, SCIENCE, (1987), vol. 235, pages 442 - 447
    - KERBEL, CARCINOGENESIS, (2000), vol. 21, pages 505 - 515
    - LYNDEN ET AL., NAT. MED., (2001), vol. 7, pages 1194 - 1201
    - HOLASH ET AL., SCIENCE, (1999), vol. 284, pages 1994 - 1998
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - TISCHER ET AL., J. BIOL. CHEM, (1991), vol. 266, pages 11947 - 11954
    - JAIN ET AL., NAT. REV. CANCER, (2002), vol. 2, pages 266 - 276
    - LYDEN ET AL., NATURE MEDICINE, (2001), vol. 7, page 1194
    - JACOB ET AL., EXP. PATHOL., (1978), vol. 15, page 1234
    - BAE ET AL., J. BIOL. CHEM., (2000), vol. 275, page 13588
    - MAYFIELD ET AL., PROC. NATL. ACAD. SCI. USA., (2003), vol. 100, no. 2, pages 438 - 42
    - SINCLAIR ET AL., PROTEIN EXPR. PURIF., (2002), pages 96 - 105
    - CONNELL N D, CURR. OPIN. BIOTECHNOL., (2001), vol. 12, no. 5, pages 446 - 9
    - MAKRIDES ET AL., MICROBIOL. REV, (1996), vol. 60, no. 3, pages 512 - 38
    - SHARP ET AL., YEAST, (1991), vol. 7, no. 7, pages 657 - 78
    - SAMBROOK ET AL., Molecular Cloning: A Laboratory Manual, 2 ed.,, COLD SPRING HARBOR LABORATORY PRESS, (1989), vol. 1-3
    - LUCKOW; SUMMERS, BIOLTECHNOLOGY, (1988), vol. 6, page 47
    - RAJU ET AL., BIOCHEMISTRY, (20001231), vol. 40, no. 30, pages 8868 - 76
    - SANDLER; KARO, Polymer Synthesis, ACADEMIC PRESS, vol. 3, pages 138 - 161
    - MONFARDINI ET AL., BIOCONJUGATE CHEM., (1995), vol. 6, pages 62 - 69
    - PEPINSKY ET AL., JPET, (2001), vol. 297, page 1059
    - WIEDER ET AL., J. BIOL. CHEM., (1979), vol. 254, page 12579
    - CHAMOW ET AL., BIOCONJUGATE CHEM., (1994), vol. 5, page 133
    - CAZALIS ET AL., BIOCONJUG. CHEM, (2004), vol. 15, no. 5, pages 1005 - 1009
    - MCLEOD ET AL., INVEST. OPHTHALMOL. VIS. SCI., (2002), vol. 43, no. 2, pages 474 - 82
    - WATANABE ET AL., EXP. DERMATOL., (2004), vol. 13, no. 11, pages 671 - 81
    - YOSHIJI ET AL., GUT., (2003), vol. 52, no. 9, pages 1347 - 54
    - VERHEUL ET AL., ONCOLOGIST, (2000), vol. 5, no. 1, pages 45 - 50
    - BOLDICKE ET AL., STEM CELLS, (2001), vol. 19, no. 1, pages 24 - 36
    - BLOOD ET AL., BIOCH. BIOPHYS. ACTA, (1990), vol. 1032, pages 89 - 118
    - MOSES ET AL., SCIENCE, (1990), vol. 248, pages 1408 - 1410
    - INGBER ET AL., LAB. INVEST., (1988), vol. 59, pages 44 - 51
    - KORNDORFER ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, (2003), vol. 53, no. 1, pages 121 - 129
    - ROQUE ET AL., BIOTECHNOL. PROG., (2004), vol. 20, pages 639 - 654
    - LEFRANC ET AL., DEV. COMP. IMMUNOL., (2005), vol. 29, pages 185 - 203
    - HONEGGER; PLUCKTHUN, J. MOL. BIOL., (2001), vol. 309, no. 3, pages 657 - 670
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 26
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 83
    - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 48
    - POLJAK ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 23
    - LEFRANC ET AL., DEV. COMP. IMMUNOL, (2005), vol. 29, pages 185 - 203
    - GLUZMAN ET AL., CELL, (1981), vol. 23, page 175
    - RASMUSSEN ET AL., CYTOTECHNOLOGY, (1998), vol. 28, page 31
    - URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 20
    - MCMAHAN ET AL., EMBO J., (1991), vol. 10, page 2821
    - LANDSCHULZ ET AL., SCIENCE, (1988), vol. 240, page 1759
    - HOPPE ET AL., FEBS LETTERS, (1994), vol. 344, page 191
    - FANSLOW ET AL., SEMIN. IMMUNOL, (1994), vol. 6, pages 267 - 78
    - KORTT ET AL., PROT. ENG, (1997), vol. 10, page 423
    - KORTT ET AL., BIOMOL. ENG., (2001), vol. 18, pages 95 - 108
    - KRIANGKUM ET AL., BIOMOL. ENG, (2001), vol. 18, pages 31 - 40
    - BIRD, SCIENCE, (1988), vol. 242, page 423
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 5879
    - WARD ET AL., NATURE, (1989), vol. 334, page 544
    - DE GRAAF ET AL., METHODS MOL. BIOL., (2002), vol. 178, pages 379 - 87
    - LANTTO ET AL., METHODS MOL. BIOL, (2002), vol. 178, pages 303 - 16
    - BLOOM ET AL., PROTEIN SCIENCE, (1997), vol. 6, page 407
    - MILSTEIN ET AL., NATURE, (1983), vol. 305, page 537
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
    - GLENNIE ET AL., J. IMMUNOL., (1987), vol. 139, page 2367
    - KOSTELNY ET AL., J. IMMUNOL., (1992), vol. 148, page 1547
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.